A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis

Running head: Sleep Disturbance in Psoriasis

A.L. Henry\textsuperscript{1,2,3}, S.D. Kyle\textsuperscript{4}, A. Chisholm\textsuperscript{5}, C.E.M. Griffiths\textsuperscript{1,3,6}, C. Bundy\textsuperscript{1,2,3}

\textsuperscript{1} Division of Musculoskeletal and Dermatological Sciences, University of Manchester, Manchester, UK
\textsuperscript{2} Manchester Centre for Health Psychology, University of Manchester, Manchester, UK
\textsuperscript{3} Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
\textsuperscript{4} Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
\textsuperscript{5} Department of Psychological Sciences, University of Liverpool, Liverpool, UK
\textsuperscript{6} Salford Royal NHS Foundation Trust, Manchester, UK

Corresponding author: Mr Alasdair L. Henry. Address: Room 1.725, Stopford Building, University of Manchester, Oxford Road, Manchester, M13 9PL. Tel: 0161 275 1866 Email: alasdair.henry@postgrad.manchester.ac.uk

Funding source: This article presents independent research funded by The Psoriasis Association of Great Britain and Ireland (R117541).

Conflicts of interest: None

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bjd.15469
This article is protected by copyright. All rights reserved.
ABSTRACT

Background

Research suggests that sleep disturbance is common in psoriasis. Despite 32 studies conducted in sleep, many demonstrate methodological flaws, often using unvalidated measurement, with no study examining multiple dimensions of sleep-wake functioning. Moreover, research has yet to comprehensively examine the range of physical and psychological factors that may affect sleep in people with psoriasis.

Objective

To characterise sleep disturbance using validated measures and identify physical and psychological predictors of sleep quality in people with psoriasis.

Methods

An online survey was conducted (n=186;M_{age}=39.2) comprising validated measures assessing sleep (Pittsburgh Sleep Quality Index [PSQI], Berlin Questionnaire, Pre-Sleep Arousal Scale), chronotype (Morningness-Eveningness Questionnaire), mood (Hospital Anxiety and Depression Scale), itch (5-D Itch Scale) and psoriasis severity (Simplified Psoriasis Index). Group comparisons and regression analyses were used to examine predictors of poor sleep.

Results

Mean PSQI score was 9.24 (SD=4.32), with 76.3% scoring above the threshold for poor sleep (≥6 on the PSQI) and 32.5% scoring ‘positive’ for probable obstructive sleep apnoea. Poor sleep and high likelihood of OSA was associated with more severe psoriasis (p<.05;
η² = .07; η² = .005). Cognitive arousal (β = .264, p = .001), itch (β = .260, p < .001) and depression (β = .236, p = .001) were the most robust predictors of poor sleep quality which, together with somatic arousal (β = .168, p = .022), accounted for 43% of variance in PSQI scores.

**Conclusions**

Poor sleep is common in psoriasis and associated with psychological and physical factors. Rates of probable obstructive sleep apnoea are also high. Given the importance of restorative sleep for health, sleep complaints should receive greater clinical attention in the management of psoriasis.

**INTRODUCTION**

Psoriasis is a complex immune-mediated inflammatory disease primarily impacting on skin and affecting 2-3% of the population worldwide. It has well established associations with a number of other conditions, including: cardiovascular disease (CVD), inflammatory bowel disease, psoriatic arthritis, diabetes, and depression and anxiety. The disease burden of psoriasis is greater than other chronic dermatological conditions and equivalent to that experienced in cancer, CVD and arthritis populations.

There is mounting interest in the relationship between sleep and psoriasis. A systematic review by our group showed that a high proportion (ranging from 0.05% to 87.5%) of individuals with psoriasis may experience sleep disturbances, which are associated with itch, psychological distress (low mood and anxiety), pain and obstructive sleep apnoea (OSA). However the published literature demonstrates substantial variation in rates of disturbed sleep, and is limited by poor measurement of sleep, with many studies using unvalidated measures, in some cases just a single question. Indeed, lack of a comprehensive and valid examination of sleep, alongside incomplete data reporting, has hindered our understanding of sleep in psoriasis.

Sleep disturbance, including OSA, is associated with a range of adverse health outcomes including elevated risk for a range of physical diseases, several of which people with psoriasis are already more susceptible to (e.g. diabetes, hypertension, CVD). Moreover, sleep disturbance increases risk of psychological illness (e.g. depression, anxiety) and, over time, all-cause mortality. Sleep is essential for metabolic and immunological health, while sleep disturbance may be pro-inflammatory and impact on psoriasis activity. Indirect evidence supporting the impact of sleep on inflammation in psoriasis comes from a recent epidemiological study showing that the presence of a comorbid sleep disorder...
increases CVD risk by 25% in psoriasis patients\textsuperscript{21}. Additionally, relationships between circadian factors and psoriasis have been identified, with a longitudinal study reporting that regular night-shift work is associated with increased risk of developing psoriasis\textsuperscript{22}. Circadian misalignment may disrupt normative metabolic and endocrine functioning, leading to adverse cardiometabolic complications, possibly through impairment of normal melatonin functioning. Melatonin, is involved in both sleep\textsuperscript{23}, and regulates inflammatory responses\textsuperscript{24}, and may lead to increased risk of psoriasis onset if chronically disrupted\textsuperscript{22}.

Based upon the strong links identified between sleep, health and psoriasis, a multidimensional assessment of sleep in this population is warranted. Whilst previous studies provide evidence of sleep disturbance in psoriasis, few studies have measured multiple domains of sleep disturbance in psoriasis patients using validated tools\textsuperscript{9}. A range of validated measures must be used to comprehensively assess the range of sleep dimensions, including sleep timing (i.e. chronotype), sleep quality, sleep continuity and sleep duration. Due to the limited appraisal of potential predictors of sleep quality in psoriasis we sought to examine the role of these in predicting poor sleep focusing on variables associated with poor sleep in psoriasis including low mood\textsuperscript{14,15,25,26}, anxiety\textsuperscript{15,27,28} and itch\textsuperscript{29,30} and more generally, pre-sleep arousal\textsuperscript{31-33}. Our aims were as follows: firstly to examine multiple dimensions of sleep-wake functioning in a representative community-based sample, and secondly, to identify the predictors of sleep disturbance, focusing on both physical and psychological variables known to interact with sleep in psoriasis.

**METHODS**

**Design**

We conducted a cross-sectional online survey using SelectSurvey.NET (v4.146.001, ClassApps, Overland Park, KS, USA). This allowed an international sample to access the survey, and enabled participants to complete it in their own time.

**Recruitment**

Links for the survey were distributed via social media sites by the Psoriasis Association of Great Britain and Ireland, the National Psoriasis Foundation, the Canadian Psoriasis Association, The British Skin Foundation, and were posted on Facebook groups for members of the New Zealand Psoriasis Association along with other psoriasis support groups. Additional snowballing techniques were used: the survey link was distributed by the
IMPACT research group’s (www.impactpsoriasis.org.uk) professional contacts, an existing psoriasis research database and through posters placed in a UK University.

**Participants**

Inclusion criteria included (i) a diagnosis of plaque psoriasis from a healthcare professional, (ii) ≥18 years old and (iii) a good understanding of English. The survey was available to any individual with psoriasis regardless of whether or not they were experiencing sleep disturbance to ensure that variation in sleep quality was captured.

**Procedure and analysis**

Upon opening the survey link, participants were presented with an information sheet explaining the study’s aims, content and research team contact details. Consent was provided online immediately preceding participation. Demographic questions, measures relating to sleep, mood, psoriasis, and itch were presented for completion and included:

**Pittsburgh Sleep Quality Index (PSQI)**[^34][^35] - Assesses sleep quality and disturbance over one month. It consists of 19 items scored across 7 components which yield a global score ranging from 0 to 21. A score of ≤5 indicates normal sleep whereas ≥6 indicates poor sleep.

**Berlin Questionnaire**[^36] – A screening questionnaire used to assess risk for the development of OSA. It consists of 3 categories containing a total of 10 items. Positive scores in >2 categories indicate high OSA risk and low risk if <1 category is positive.

**Morningness-Eveningness Questionnaire (MEQ)**[^37] – Ascertains when an individual’s peak alertness is (morning, evening or in between) over 19 multiple choice questions. Scores correspond to the following chronotypes: 16-30 – definite evening, 31-41 – moderate evening, 42-58 – intermediate, 59-69 – moderate morning, and 70-86 – definite morning.

**Pre-Sleep Arousal Scale (PSAS)**[^38][^39] - Quantifies cognitive and somatic arousal during the pre-sleep period. It consists of 16 items across 2 subscales, one assessing cognitive arousal and the other somatic arousal with scores ranging from 8 to 40. A higher score indexes greater pre-sleep arousal.

**Hospital Anxiety and Depression Scale (HADS)**[^40][^41] – An established measure of depression and anxiety comprising 14 items, with 7 relating to depression and 7 relating to anxiety (each subscale scored between 0 and 21). A higher score reflects greater distress. A cut-off score of 9 for each subscale indicates ‘caseness’ for probable clinical levels of distress[^41].

[^34]: [as reference]
[^35]: [as reference]
[^36]: [as reference]
[^37]: [as reference]
[^38]: [as reference]
[^39]: [as reference]
[^40]: [as reference]
[^41]: [as reference]
Simplified Psoriasis Index-Severity Score (SPI-S) – A self-assessment of psoriasis severity asking participants to rate the extent and plaque thickness which are multiplied to obtain a severity score. Scores range from 0-50 with a higher score indicating more severe psoriasis. An SPI-S score of <5, <10, >18, >19 and >20 is equivalent to a Psoriasis Area Severity Index score of <5, <10, >15, >18 and >20 respectively.

5-D Itch Scale – A measure of the degree, duration, direction, disability and distribution of itch. It can be calculated to provide a global score of itch severity and impact. Scores can range from 5 (no itch) to 25 (severe itch).

All questions on each page had to be completed in order to progress to the next page. Ethical approval for this study was obtained in June 2015 (ref: 15/LO/1052).

Statistical analyses

Descriptive data were obtained for all variables. Normality was assessed and due to positively skewed data, bootstrapping based upon 5000 replications was applied to tests using psoriasis severity. Associations between questionnaire variables were tested using Pearson's product moment correlations and point-biserial correlations when using OSA probability. Independent t-tests were used to compare psoriasis severity scores for normal (PSQI≤5) and poor sleepers (PSQI≥6) and to compare psoriasis severity scores between those with a high and low likelihood for OSA. A one-way analysis of variance (ANOVA) compared psoriasis severity scores for morning, intermediate and evening chronotype groups. Relative between-group effect sizes, expressed as eta-squared ($\eta^2$), were applied to estimate and compare the magnitude of observed effects. To examine which factors predicted poor sleep a multiple linear regression was performed for all variables that correlated with sleep ($r \geq 0.4$) entered simultaneously. All analyses were conducted on SPSS (v22.0, IBM Corporation; Armonk, NY, USA).

RESULTS

Sample characteristics

One hundred and eighty-six people (140 [75.3%] female; $M_{\text{age}} = 39$ years; range 18-70 years) from 15 countries (UK, USA, Canada, New Zealand, Australia, Ireland, Germany, Greece, Argentina, Egypt, India, France, Italy, Denmark, Puerto Rico) completed the survey between June 2015 and January 2016, providing complete data. Partial data was obtained from 241 participants, however, many dropped out in the initial pages of the survey. Rather
than substitute data for partially complete responses we chose to use complete data only.
Psoriasis severity was predominantly mild with a sample mean SPI-S score of 9.56 (SD=8.58). Mean score for the depression and anxiety subscales were below the clinical threshold at 6.52 (SD=4.24) and 8.56 (SD=4.34) respectively.\(^\text{41}\)

**Sleep Characteristics**

Of 186 participants, 76.3% (n=142) were classified as poor sleepers with the sample having a mean PSQI score of 9.24, SD=4.32. Sixty-one (32.6%) participants had a high probability of OSA as determined by the BQ. Consistent with elevated OSA probability, the mean BMI for the sample was high at 30.7 kg/m\(^2\), with 26.4% overweight (>25 kg/m\(^2\)) and 44.8% obese (>30 kg/m\(^2\)). Regarding pre-sleep arousal, the mean score for the cognitive subscale was 21.01 (SD=7.5) and 14.53 (SD=5.85) for the somatic subscale. The mean MEQ score for the sample was 51.43 (SD=9.98), with the majority possessing an intermediate chronotype (62.9%), followed by morning (23.1%) then evening (14%).

Participants' mean total sleep time was 371.3 (SD=89.14) minutes with 83.3% classified as short sleepers (<7 hours), 14.5% as normal sleepers (7-9 hours) and 2.2% as long sleepers (>9 hours).\(^\text{46}\) Mean sleep efficiency for the sample was relatively poor at 75.34% (SD=17.33), with a mean sleep onset latency of 42.37 (SD=44.04) minutes. Reported sleep problems related to poor subjective sleep quality (51%) two or more times per week, difficulties initiating sleep (52.1%) two or more times per week and difficulty with both maintaining sleep along with early awakening from sleep (79%) two or more times per week. Participants' also reported difficulties sleeping due to being too hot and experiencing pain. Further detail on these can be seen in S1.

Descriptive data for all variables are presented in Table 1. Comparisons of mean scores for normal and poor sleepers for each continuous measure can be seen in Figure 1.

A significant difference was present in psoriasis severity scores between normal sleepers (M=6.36; SD=5.44) and poor sleepers (M=10.55; SD=9.14 t(184)=3.73, p<.001, \(\eta^2=.07\)), with poor sleepers having significantly higher psoriasis severity scores. Similarly, individuals with a high probability of OSA (M=11.58, SD=10.30) had significantly higher psoriasis severity scores than those with a low probability (M=8.58, SD=7.45 t(184) = 2.03, p<.05, \(\eta^2=.005\)). There were no significant differences in psoriasis severity scores between morning (M=7.75, SD=6.86), intermediate (M=10.19, SD=8.69), and evening (M=9.69, SD=10.39) chronotype groups, (p=.281; \(\eta^2=.014\)).
Predictors of sleep quality

Next, we evaluated the contribution of variables (age, sex, BMI, psoriasis severity, mood, itch, pre-sleep arousal, chronotype and OSA risk) to variation in sleep quality. Sleep quality was significantly positively correlated with psoriasis severity, anxiety, depression, itch, somatic arousal and cognitive arousal and negatively correlated with chronotype (Table 2). All variables except psoriasis severity, chronotype and OSA probability correlated with sleep quality at \( r \geq .4 \). Therefore, anxiety, depression, itch, and somatic and cognitive arousal were included in the subsequent regression analysis (Table 3).

Multiple regression analysis indicated that cognitive arousal (\( \beta = .264, p<.05 \)), itch (\( \beta = .260, p<.0001 \)), depression (\( \beta = .236, p<.05 \)) and somatic arousal (\( \beta = .168, p<.05 \)) were independent predictors of sleep quality, together accounting for 43% of variance in PSQI scores.

DISCUSSION

The aim of this study was to characterise sleep in psoriasis and to examine the predictors of sleep quality. Our results show that poor sleep quality may be more common in psoriasis (76.3%) than estimates in the general population (30-50%)\(^47\). Indeed, sleep quality and sleep efficiency were worse than previously reported in psoriasis \(^{48-50}\) or diabetes samples\(^51\) and equivalent to that shown in a psoriatic arthritis sample\(^52\). Additionally, we observed a high probability of OSA in our sample (32.5%), again at a rate higher than the prevalence in the general population (3-7%)\(^53\), although somewhat lower than the rate of around 50% reported in other psoriasis samples\(^54\)\(^55\).

Short sleep duration (<7 hours) was common in our sample, reported by the majority (83.3%). Short sleep duration has well established links with negative health consequences including obesity\(^56\), diabetes\(^57\)\(^58\) and hypertension\(^59\) and thus may contribute to increased disease burden. Participants reported difficulties initiating and maintaining sleep, alongside early awakening with an inability to resume sleep; these are core features of insomnia\(^60\). Indeed, there was high pre-sleep cognitive and somatic arousal in our sample, at least as high as clinical insomnia patients\(^61\). Pre-sleep arousal is a known feature of insomnia, frequently precipitating and contributing to sleep difficulties\(^31\)\(^62\) manifesting as cognitive (rumination, worry and negative emotion)\(^32\), somatic (elevated sympathetic activity,
metabolic rate and hypothalamic-pituitary-adrenal axis activity)\textsuperscript{63-65} and cortical (increased brain metabolism and high-frequency EEG activity)\textsuperscript{66, 67} hyper-arousal.

The elevated OSA probability present in our sample is consistent with the high mean BMI score found, with obesity a known risk factor for OSA\textsuperscript{68} and common in people with psoriasis\textsuperscript{69}. It is likely that lifestyle factors (e.g. obesity, physical inactivity) are involved and may contribute to this elevated risk\textsuperscript{55}. Nevertheless, it has been proposed that psoriasis and OSA are linked bi-directionally via inflammatory pathways, with both disorders demonstrating increased concentrations of interleukin (IL)-17, IL-6 and tumour necrosis factor (TNF)-\textalpha\textsuperscript{70-73}.

Whilst the precise mechanisms linking OSA and psoriasis remain unclear, there is some evidence suggesting links between lifestyle factors and CVD/hypertension may underlie this elevated risk\textsuperscript{74}. It is worth mentioning that OSA estimates in this study are lower than reported elsewhere\textsuperscript{6} and may be due to the use of a self-report measure (Berlin Questionnaire) rather than polysomnography to assess OSA. However, the Berlin Questionnaire has proven validity, and a moderate-strong positive predictive value, ranging from \textalpha\textsuperscript{75} to \textalpha\textsuperscript{96}. Given that OSA is a known risk factor for CVD\textsuperscript{76}, ischemic stroke\textsuperscript{77}, road traffic accidents\textsuperscript{78} and hypertension\textsuperscript{79} we suggest that sleep disordered breathing is queried in patients with psoriasis to facilitate appropriate diagnosis and treatment.

Cognitive arousal, itch, depression and somatic arousal were identified as key predictors of sleep quality. Elevated arousal in the pre-sleep period is associated with sleep difficulties in insomnia and healthy individuals, contributing to increased sleep onset latency, reduced sleep efficiency and total sleep time and sleep-state misperception\textsuperscript{31-33}. Although speculative, a number of factors may contribute to elevated arousal in psoriasis including disease-related rumination and worry, and monitoring of somatic symptoms, such as itch.

Further arousal may stem from disrupted emotional regulation, resulting in negatively-toned emotional activity with sleep disturbances known to modulate emotional responses\textsuperscript{80, 81}. It is likely that anxiety did not emerge as a significant predictor due to the probable shared variance between the HADS-A and PSAS-C subscales. The content of this elevated arousal in the pre-sleep period could be investigated further, examining psoriasis-specific factors. Itch and associated scratching have been reported as disrupting sleep in psoriasis and other pruritic conditions, with scratching occurring throughout the sleep period\textsuperscript{82-85}. Evidence suggests conditioned scratching activity can occur during sleep, with nocturnal scratching reported as a distinct parasomnia in a number of cases\textsuperscript{96}. Moreover, itch has strong links with mood\textsuperscript{87}, with depression amplifying itch perception\textsuperscript{88}. In addition, well-established links between depression and sleep exist, with low mood and insomnia interacting bidirectionally\textsuperscript{14} suggesting the existence of shared aetiology\textsuperscript{14, 26}. Future research could focus on
prospectively examining the causal direction between these predictors and poor sleep with the aim of identifying possible mediating pathways.

A key strength of this study is that it provides a multidimensional assessment of sleep using validated measures in an international sample. Despite this, there are limitations that must be considered. First, our study may have been subject to selection bias with people that experience sleep disruption having a greater motivation to participate. We attempted to minimise this by inviting all individuals with psoriasis regardless of sleep status to participate. Moreover, although the majority of our sample had mild psoriasis, magnitude of sleep disturbance and high levels of pre-sleep arousal suggest that poor sleep is a prevalent issue in this group. We believe the distribution of psoriasis severity observed in this study is sufficiently similar to that found elsewhere. It is unclear, however, why there was a predominance of women participating in the study. It could be speculated that this is due to a higher prevalence of insomnia, thus may be the result of selection bias. Indeed, evidence suggests women are more likely to respond to survey research with similar gender distributions to those encountered here observed in other sleep-related survey studies. It is also unclear why we obtained a low participation rate relative to the recruitment efforts. Over 11,800 individuals engaged with the survey link, however 11,471 did not continue past the information sheet. We are unsure why this is, however, a contributing factor may have been the number of questions included. Another significant limitation of this study is the lack of a control group, limiting our ability to generalise the prevalence of sleep disturbance found in this study to the psoriasis population as a whole. A further limitation stems from the use of subjective sleep measures, which, whilst valid, were retrospective in nature and thus may be subject to recall biases which is a limitation of cross-sectional research. Additionally, we did not examine other sleep disorders such as sleep-related movement disorders, circadian rhythm disorders, parasomnias or excessive daytime sleepiness; thus hidden sleep pathology may not have been detected. Finally, with the study being cross-sectional we are limited in our ability to explore the causal ordering of variable relationships.

In summary, our findings suggest that sleep disturbance more common than previously thought in psoriasis and that it is associated with a range of psychological and physical factors. Whilst a handful of studies have shown improvements in sleep in psoriasis following administration of biologic medication, this should be combined with psychological therapies specifically targeting the modifiable factors identified here including, including itch, negative mood and pre-sleep arousal. Therapeutic focus on these variables may lead to improvements in sleep in people with psoriasis.
REFERENCES


70. Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators of Inflammation 2005;2005(5):273-79.

This article is protected by copyright. All rights reserved.
<table>
<thead>
<tr>
<th>Variable</th>
<th>Score</th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, % male/female</td>
<td>24.7/75.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>39.2 (12.63)</td>
<td>18</td>
<td>70</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>30.7 (9.37)</td>
<td>13.15</td>
<td>78.9</td>
</tr>
<tr>
<td>Alcohol, mean (SD), units per week</td>
<td>4.21 (9.35)</td>
<td>0</td>
<td>70</td>
</tr>
<tr>
<td>PSQI score, mean (SD)</td>
<td>9.24 (4.32)</td>
<td>2</td>
<td>20</td>
</tr>
<tr>
<td>Normal sleepers (≤5), n (%)</td>
<td>44 (23.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor sleepers (≥6), n (%)</td>
<td>142 (76.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSA probability</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low, n (%)</td>
<td>125 (67.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High, n (%)</td>
<td>61 (32.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSAS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognitive Arousal, mean (SD)</td>
<td>21.01 (7.5)</td>
<td>8</td>
<td>40</td>
</tr>
<tr>
<td>Somatic Arousal, mean (SD)</td>
<td>14.53 (5.84)</td>
<td>8</td>
<td>33</td>
</tr>
<tr>
<td>MEQ, mean (SD)</td>
<td>51.43 (9.98)</td>
<td>19</td>
<td>75</td>
</tr>
<tr>
<td>Morning type, n (%)</td>
<td>43 (23.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate type, n (%)</td>
<td>117 (62.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evening type, n (%)</td>
<td>26 (14)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itch, mean (SD)</td>
<td>13.99 (4.27)</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>Psoriasis severity, mean (SD)</td>
<td>9.56 (8.58)</td>
<td>0</td>
<td>48</td>
</tr>
<tr>
<td>Mild, n (%)</td>
<td>110 (59.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate, n (%)</td>
<td>57 (30.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe, n (%)</td>
<td>19 (10.2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HADS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression, mean (SD)</td>
<td>6.52 (4.24)</td>
<td>0</td>
<td>20</td>
</tr>
<tr>
<td>Anxiety, mean (SD)</td>
<td>8.56 (4.34)</td>
<td>0</td>
<td>21</td>
</tr>
</tbody>
</table>

*Scores range from 0-21, higher values indicate poorer sleep
bScores range from 0-50, higher values represent more severe psoriasis

Abbreviations: BMI: Body Mass Index, PSQI: Pittsburgh Sleep Quality Index, OSA: Obstructive Sleep Apnea, PSAS: Pre-sleep arousal scale, MEQ: Morningness-Eveningness Questionnaire, HADS: Hospital Anxiety and Depression Scale

<table>
<thead>
<tr>
<th>Variables</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Sleep quality (PSQI)</td>
<td></td>
<td>.337*</td>
<td></td>
<td>.435*</td>
<td></td>
<td>.496*</td>
<td></td>
<td>.452*</td>
<td></td>
<td>.484*</td>
<td></td>
<td>.462*</td>
</tr>
<tr>
<td>2. Psoriasis (SPI-S)</td>
<td>.227*</td>
<td></td>
<td>.336*</td>
<td></td>
<td>.550*</td>
<td></td>
<td>.236*</td>
<td></td>
<td>.061</td>
<td></td>
<td>-.075</td>
<td></td>
</tr>
<tr>
<td>3. Anxiety (HADS-A)</td>
<td>.517*</td>
<td></td>
<td>.267*</td>
<td></td>
<td>.557*</td>
<td></td>
<td>.641*</td>
<td></td>
<td>-.105</td>
<td></td>
<td>.252*</td>
<td></td>
</tr>
<tr>
<td>4. Depression (HADS-D)</td>
<td>.390*</td>
<td></td>
<td>.459*</td>
<td></td>
<td>.346*</td>
<td></td>
<td>-.102</td>
<td></td>
<td>.348*</td>
<td></td>
<td>.036</td>
<td></td>
</tr>
<tr>
<td>5. Itch (SD Itch Scale)</td>
<td></td>
<td>.357*</td>
<td></td>
<td>.178*</td>
<td></td>
<td>-.156*</td>
<td></td>
<td>.186*</td>
<td></td>
<td>.040</td>
<td></td>
<td>.021</td>
</tr>
<tr>
<td>6. Somatic Arousal (PSAS-S)</td>
<td>.477*</td>
<td></td>
<td></td>
<td>.131</td>
<td></td>
<td>.299*</td>
<td></td>
<td>.033</td>
<td></td>
<td>.124</td>
<td></td>
<td>.085</td>
</tr>
<tr>
<td>7. Cognitive Arousal (PSAS-C)</td>
<td>-.227*</td>
<td></td>
<td></td>
<td>.141</td>
<td></td>
<td>.047</td>
<td></td>
<td>.080</td>
<td></td>
<td>.051</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Chronotype (MEQ)</td>
<td></td>
<td>-.013</td>
<td></td>
<td>.244*</td>
<td></td>
<td>.088</td>
<td></td>
<td>.054</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. OSA probability (Berlin Questionnaire)</td>
<td></td>
<td>.139</td>
<td></td>
<td>.24</td>
<td></td>
<td>.268*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. BMI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p<.05
<table>
<thead>
<tr>
<th>Predictor</th>
<th>b</th>
<th>SE</th>
<th>β</th>
<th>t</th>
<th>p</th>
<th>R²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Itch</td>
<td>.263</td>
<td>.063</td>
<td>.260</td>
<td>4.16</td>
<td>.000</td>
<td>.430</td>
</tr>
<tr>
<td>Cognitive Arousal</td>
<td>.152</td>
<td>.043</td>
<td>.264</td>
<td>3.54</td>
<td>.001</td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>.241</td>
<td>.071</td>
<td>.237</td>
<td>3.39</td>
<td>.001</td>
<td></td>
</tr>
<tr>
<td>Somatic Arousal</td>
<td>.124</td>
<td>.054</td>
<td>.168</td>
<td>2.31</td>
<td>.022</td>
<td></td>
</tr>
<tr>
<td>Anxiety</td>
<td>-.020</td>
<td>.083</td>
<td>-.020</td>
<td>-.24</td>
<td>.809</td>
<td></td>
</tr>
</tbody>
</table>

Dependent variable: Sleep quality (PSQI total)

b, unstandardised regression coefficient; SE, standard error; β, standardised regression coefficient; t, obtained t-value; p, probability; R², proportion of variance explained